Introduction
Monoclonal antibodies (MAb), such as alemtuzumab, that are directed against immune system cells, have helped to reduce the risks of graft versus host disease (GvHD) and graft rejection after allo-HSCT. Because these benefits are produced in part by increased immunosuppression, there is a corresponding rise in post-transplant viral infection/ reactivation potentially including human herpes virus-6 (HHV-6). Approximately 33-47% allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients develop HHV-6 viremia. [1] [2] [3] Although the clinical significance of asymptomatic viremia as detected by positive HHV-6 PCR amplification of plasma is unclear, it has been linked to increased all cause mortality, post-transplant hepatitis, pneumonitis, myelosuppression and encephalitis. [1] [2] [3] [4] [5] [6] [7] [8] We now report the onset of HHV-6 encephalitis in 5/43 (11%) patients who received alemtuzumab to support their conditioning regimen for allo-HSCT. Our results emphasize that although routine monitoring of plasma HHV-6 may be unhelpful in predicting the subsequent onset of encephalitis, 4-8 a high incidence of suspicion for HHV-6 encephalitis is required in recipients of MAb-supported allo-HSCT, since prompt intervention (based on confirmation from viral DNA in cerebrospinal fluid (CSF)) can lead to an excellent outcome.
Methods

Patients
The study was approved by our Institutional Review board (IRB).
Between, January 2004 and September 2006, a total of 43 consecutive patients underwent alemtuzumab assisted in vivo T cell-depleted allo-SCT. The clinical and laboratory data were collected prospectively and medical charts were reviewed for patient demographics, disease and transplantrelated characteristics (Table 1) . GvHD prophylaxis consisted of tacrolimus alone. Viral prophylaxis consisted of valciclovir unless patients were already on active treatment for CMV antigenemia with valganciclovir or ganciclovir. None of the patients received prior intrathecal therapy or cranial irradiation. Engraftment was defined as neutrophils 4500 cells/ml, platelets 420 000 cells/ml (in the absence of transfusion) for 3 consecutive days.
GvHD
GvHD was defined and graded according to standard criteria.
Diagnosis and treatment of HHV-6 encephalitis
Lumbar puncture was performed under radiologic guidance. Both CSF and concurrent blood specimens were sent for HHV-6 analysis to a reference laboratory (Viracor, Lee's Summit, MO, USA). PCR analysis is detailed elsewhere. 10 Routine testing for HHV-6 in the absence of neurologic manifestation was not performed, but weekly HHV-6 quantitative PCR was performed once the diagnosis of encephalitis was made. CSF was routinely screened for bacterial, fungal and viral isolates, including herpes simplex virus (HSV), VZV and CMV, and also analyzed by cytology and flow-cytometry.
HHV-6 encephalitis was defined as neurologic manifestations in conjunction with positive CSF analysis for HHV-6 DNA in the absence of any other identifiable etiology. For positive patients, foscarnet was administered at 60 mg/kg intravenously 2-3 times daily until PCR negativity in blood and or CSF. An autopsy of the brain was performed in patient no. 2. Tables 1 and 2 show patient demographics and transplant characteristics. All 43 patients received alemtuzumab (total dose 40 mg) supported conditioning. Of the five patients who developed HHV-6 encephalitis, three patients had received a fully ablative conditioning regimen (CY/TBI), and two received reduced intensity conditioning (FLU/ TBI ¼ 1, FLU/MEL ¼ 1). In the 38 patients with no HHV-6 encephalitis, conditioning comprised of fludarabine, total body irradiation (450 cGy) and alemtuzumab; 17 patients received additional CD45 monoclonal antibody. Peripheral blood was the source of stem cells for all five patients, and in four, the source was a matched unrelated donor (MRD) and in one a mismatched related donor (MMRD). In the group without encephalitis, the source of stem cells was peripheral blood and bone marrow in 33 and five respectively originating from 12-MRD, 3-MMRD, 16-MUD and 7-MMUD. Primary disease that necessitated hematopoietic transplant in the encephalitis group included, AML ¼ 2, DLBCL ¼ 2 and T cell lymphoma ¼ 1 (Table 1 ) and in those without HHV-6 encephalitis,
Results
All patients received tacrolimus as GvHD prophylaxis. Neutrophil and platelets engraftment occurred at a median of 11 (range, 10-12) and 12 days (range, 9-17) respectively and all five had 100% donor chimerism. All five patients with encephalitis developed aGvHD (grade II ¼ 1, grade III ¼ 2, grade IV ¼ 2) necessitating treatment with methyl prednisone ¼ 5, infliximab ¼ 1, alemtuzumab ¼ 1 and daclizumab ¼ 1. Ten of 38 patients (26.3%) with no encephalitis developed grade II or more GvHD (grade II ¼ 6, grade III ¼ 2, grade IV ¼ 2). Overall incidence of grade III and more GvHD was 80 and 10.5% respectively in those with and without HHV-6 encephalitis (P ¼ 0.003). All other disease and transplant-related variables were not statistically different between these two groups.
HHV-6 encephalitis manifested at a median of 60 days (range, 41-103) with confusion in all patients (n ¼ 5), associated either with amnesia (n ¼ 3) or with seizures (n ¼ 2). MRI (T2 weighted) with and without contrast revealed non-enhancing medial temporal lobe lesion in three patients, whereas two had nonspecific white matter changes. CSF protein was elevated in four patients (Table 2) , with a minimal CSF lymphocytosis (median of 3 lymphocytes/hpf range, 0-48). Peripheral blood (plasma) HHV-6 PCR revealed a median of 1200 DNA copies/ml (range 100-22 500 copies/ml) in four and one patient (UPN no. 1) had negative plasma HHV-6 PCR. By contrast, CSF PCR was strongly positive in all five patients at a median of 4700 copies/ml (range, 600-2 25 000 copies/ml). EEG was nonspecific in all five patients. Viral prophylaxis in patients preceding HHV-6 encephalitis included valciclovir (n ¼ 4) and valganciclovir (n ¼ 1). Administration of intravenous Prompt recognition of HHV6 encephalitis is crucial T Vu et al foscarnet resulted in virological and neurological improvement. Plasma HHV-6 became PCR-negative at a median of 37 days (range, 30-66), whereas CSF PCR became negative on day 50 in the patient with CSF positive PCR and negative plasma PCR (UPN no. 1). CSF-PCR was not repeated in patients who achieved plasma PCR negativity and had marked clinical improvement. Confusion was the first neurological symptom to improve; a median of 11 days after treatment began, and was followed by a reduction in seizure frequency and severity. Recovery of short-term memory loss was much slower, with frequent fluctuations in severity over the ensuing weeks. Four patients had complete neurological recovery, but in patient (UPN no. 2), there was only transient neurological improvement accompanied by clearance of plasma HHV-6, and a worsening of neurological symptoms was associated with persistently measurable CSF HHV-6 DNA. She succumbed to progressive encephalopathy on day þ 147; autopsy of brain revealed bilateral extensive loss of hippocampal neurones and gliosis.
Discussion
Asymptomatic reactivation of HHV-6 after stem cell transplantation (SCT) is commonly seen when plasma is analyzed by PCR amplification, so that demonstration of viremia in asymptomatic patients is considered inconsequential. 11-15 HHV-6 may be integrated in the DNA adding further to the incidence of asymptomatic viral detection. 16 In a proportion of patients, however, significant neurological manifestations become evident. Diagnosing HHV-6 in these patients may be challenging, since approximately 25% of fully ablative allogeneic transplant recipient develop neurologic manifestations related principally to various infections, drug toxicity, metabolic abnormality and EBV related lymphoma. 17 Promptly distinguishing, diagnosing and treating HHV-6 encephalitis within this high rate of neurological morbidity is made yet more difficult by reports of asymptomatic elevation of CSF HHV-6-PCR. 5, 15 Establishing a diagnosis of HHV-6 encephalitis therefore requires the triad of neurological manifestations, evidence of HHV-6 infection in CSF (since plasma HHV-6 may be negative), and the absence of other pathogens or pathology. Because viral DNA has been demonstrated in the CSF of asymptomatic immunecompromised patients, PCR amplification of CSF for HHV-6 is not recommended in the absence of symptoms. All five patients described in this report had the necessary diagnostic triad, and all responded virologically and symptomatically to treatment, although incompletely in one case.
A number of risk factors increase the risk of HHV-6 reactivation and disease. In an analysis of 110 allogeneic transplant recipients, 4CR 1 hematologic malignancy, younger age, sex mismatch, and steroid therapy were associated with HHV-6 reactivation. 2 GvHD, with its accompanying immunosuppression, also increases the risk of HHV-6 encephalitis. In our group, all five affected patients had had acute GvHD (grade II ¼ 1, grade III ¼ 2, grade IV ¼ 2) compared with 10/38 (26.3%) Although there are several reports that incorporation of alemtuzumab increases the frequency and perhaps the severity of CMV reactivation after allo-HSCT, 18 there are as yet no data to show an increased risk for reactivation of other herpes viruses. Nonetheless, the increased depletion of both host and incoming donor T cells produced by alemtuzumab during its 20 day þ half life would be predicted to adversely influence time to recovery of endogenous immunity to HHV-6 and the high incidence observed in the current series is consistent with such an effect. It will be of interest to discover whether other T cell depleting antibodies used in conditioning regimens such as anti-thymocyte globulin (ATG) and the humanized CD3 antibody (Visilizumab) lead to the same predisposition to HHV-6 reactivation, or whether the effects of CD52 antibody are unique, and a consequence of a different target cell specificity or half-life.
Our patients followed the known predilection of HHV-6 to involve the medial temporal lobe and hippocampi, followed by the amygdala or parahippocampal gyrus. This pattern of involvement manifests clinically as acute hippocampal dysfunction (loss of short-term memory, sleep disturbances and confusion). 19 This constellation of symptoms may raise the suspicion of HHV-6 encephalitis, but the disease may also present less specifically with headache, seizure, coma and fever. 20 Since prompt treatment with foscarnet can be highly successful, it is important to investigate immediately and vigorously suspicious symptoms and signs of the disease by appropriate imaging and CSF studies, and to maintain antiviral treatment for more than 7 days. 21 Given its apparent frequency, is routine prophylaxis of HHV-6 in alemtuzumab recipients worthwhile? A few studies of prophylaxis in a small number of patients do appear to show a lower incidence of HHV-6 reactivation. In a case controlled study of 16 patients on either acyclovir (ACV) or ganciclovir (GCV), three of eight (37%) in the ACV arm developed HHV-6 reactivation compared to 0 of six patients receiving GCV. 22 Another small study 23 reported 11 of 28 allo-SCT patients with HHV-6 reactivation (all outside the CNS), as opposed to none of the 13 patient who were on prophylactic GCV. Although these are encouraging data, it is noteworthy that one of our patients was already receiving 'optimal' prophylaxis (valganciclovir given for CMV reactivation) at the time HHV-6 encephalitis was diagnosed. Clearly, additional assessments of incidence will be needed before we can decide whether additional prophylaxis with foscarnet or GCV is safe and cost effective in alemtuzumab recipients, or whether prompt diagnosis and treatment are preferable. We conclude that patients receiving alemtuzumab assisted in vivo T cell-depletion who develop GvHD may be at increased risk of HSV-6 encephalitis. Since routine CSF, MRI and EEG all give a limited diagnostic yield when used alone, a high index of clinical suspicion and CSF examination for HHV-6 PCR is essential when these patients develop even mild symptoms of limbic dysfunction or encephalopathy.
